Drima Eduard

Dr. Drima Eduard

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2015 in Annals of General Psychiatry
Verified
Journal Article
Open access
PDF file
MVMădălina Vrabie
Mădălina Vrabie
VMVictor Marinescu
Victor Marinescu
ACAnca Ana Chendea
Anca Ana Chendea
OTOana Tăutu
Oana Tăutu
DEDrima Eduard
Drima Eduard
IMIoana Valentina Micluţia
Ioana Valentina Micluţia
Bipolar disorder is a chronic mood disorder with episodic progress and high relapse rate. Growing evidence suggests that individuals with bipolar disorder display cognitive impairment which persists even throughout periods of symptom's remission. 137 bipolar patients met the inclusion criteria (depressive episode: DSM-IV-TR criteria for major depressive episode, HAMD score ≥17; manic/hypomanic episode: DSM-IV-TR criteria for manic/hypomanic episode, YMRS score ≥12, euthymic: 6 months of remission, HAMD score ≤8, YMRS score ≤6; and mixed: DSM-IV-TR criteria for mixed episode, HAMD score >8 and YMRS score >6) and were therefore enrolled in the study. Patients were free of psychotic symptoms (hallucinations/delusions) at the moment of testing. Control group consisted of 62 healthy subjects without history of neurological and/or psychiatric disorder. Cognitive battery has been applied in order to assess verbal memory, working memory, psychomotor speed, verbal fluency, attention and speed of information processing, and executive function. Following data were collected: demographics, psychiatric history, age of illness onset; current and previous treatment (including hospitalizations). Cognitive deficits were assessed in bipolar patients experiencing manic, depressive, mixed episodes or who were euthymic in mood. Results were compared between the subgroups and with healthy individuals. The association of impaired cognition with illness course was analyzed. Bipolar patients showed cognitive deficits in all evaluated domains when compared to controls. The lowest scores were obtained for the verbal fluency test. After adjusting for current episode, manic subgroup showed greater cognitive impairment in verbal and working memory, executive function/reasoning and problem solving, compared to depressive, mixed, and euthymic subgroup. Low-neurocognitive performance was directly associated with a predominance of manic episodes and severe course of bipolar illness. An increased number of past manic episodes was the strongest correlated event with the poorest outcomes in verbal memory testing. Other factors correlated with poor verbal memory scores in manic subgroup were age at illness onset (positive correlation), illness length, and hospitalizations (negative correlations). Bipolar patients showed cognitive deficits regardless of the phase of illness. Subjects experiencing a manic episode displayed higher deficits in verbal and working memory, executive function/reasoning, and problem solving. Severe course of illness also showed significant contribution in terms of cognitive impairment.

1 June 2019 in Regenerative Therapy
Verified
Journal Article
Open access
Sorin HostiucSorin Hostiuc
Sorin Hostiuc
Mugurel Constantin RusuMugurel Constantin Rusu
Mugurel Constantin Rusu
Ionut NegoiIonut Negoi
Ionut Negoi
PPPaula Perlea
Paula Perlea
BDBogdan Dorobanţu
Bogdan Dorobanţu
DEDrima Eduard
Drima Eduard
Organoids are 3D biological structures constructed from stem cells in vitro. They partially mimic the function of real organs. Although the number of articles detailing this technology has increased in recent years, papers debating their ethical issues are few. In addition, many of such articles outline a mere summary of potential ethical concerns associated with organoids, although some have focused on consciousness assessment or organoid use in cystic fibrosis treatment. This article seeks to evaluate the moral status of cerebral organoids and to determine under which conditions their use should be allowed from a bioethical standpoint. We will present an overview of recent steps in developing highly advanced cerebral organoids, followed by an analysis of their ethics based on three factors: human origin, a specific biological threshold (which, once crossed, grants an entity moral status), and the potential to generate human beings. We will also make practical recommendations for researchers working in this biological field.

12 February 2018 in Frontiers in Pharmacology
Verified
Journal Article
Open access
Sorin HostiucSorin Hostiuc
Sorin Hostiuc
Alin Dragoș Bogdan MoldoveanuAlin Dragoș Bogdan Moldoveanu
Alin Dragoș Bogdan Moldoveanu
INIonuţ Negoi
Ionuţ Negoi
DEDrima Eduard
Drima Eduard
Background. In the last years were published many epidemiological articles aiming to link driving under the influence of cannabis with the risk of various unfavorable traffic events, with sometimes contradictory results. Aim. The primary objective of this study was to analyse whether there is a significant association between druving under the influence of cannabis and unfavorable traffic events. Materials and methods. We used two meta-analytical methods to assess the statistical significance of the effect size: random effects model and inverse variance heterogeneity model. Results. 24 studies were included in the meta-analysis. we obtained significant increases in the effect size for driving under the influence of cannabis tested through blood analysis, with an Odds Ratio (OR) of 1.27 and a Confidence Interval (CI) between 1.36-3.80, death as an outcome, with an OR of 1.56, and a CI between 1.16 and 2.09, and case-control as the type of study, with an OR of 1.99 and a CI between 1.05 and 3.80. Publication bias was very high. Conclusion. Our analysis suggests that the overall effect size for driving under the influence of cannabis on unfavorable traffic events is not statistically significant, but there are significant differences obtained through subgroup analysis. This result might be caused by either methodological flaws (which are often encountered in articles on this topic), the indiscriminate employment of the term “cannabis use” or an actual absence of an adverse effect. When a driver is found, in traffic, with a positive reaction suggesting cannabis use, the result should be corroborated by either objective data regarding marijuana usage (like blood analyses, with clear cut-off values), or a clinical assessment of the impairment, before establishing his/her fitness to drive.

5 January 2018 in BMC Psychiatry
Verified
Journal Article
Open access
PDF file
Sorin HostiucSorin Hostiuc
Sorin Hostiuc
Mugurel Constantin RusuMugurel Constantin Rusu
Mugurel Constantin Rusu
Ionut NegoiIonut Negoi
Ionut Negoi
DEDrima Eduard
Drima Eduard
The process of assessing the decision-making capacity of potential subjects before their inclusion in clinical trials is a legal requirement and a moral obligation, as it is essential for respecting their autonomy. This issue is especially important in psychiatry patients (such as those diagnosed with schizophrenia). The primary purpose of this article was to evaluate the degree of impairment in each dimension of decision-making capacity in schizophrenia patients compared to non-mentally-ill controls, as quantified by the (MacCAT-CR) instrument. Secondary objectives were (1) to see whether enhanced consent forms are associated with a significant increase in decision-making capacity in schizophrenia patients, and (2) if decision-making capacity in schizophrenia subjects is dependent on the age, gender, or the inpatient status of the subjects. We systematically reviewed the results obtained from three databases: ISI Web of Science, Pubmed, Scopus. Each database was scrutinised using the following keywords: “MacCAT-CR + schizophrenia”, “decision-making capacity + schizophrenia”, and “informed consent + schizophrenia.” We included 13 studies in the analysis. The effect size between the schizophrenia and the control group was significant, with a difference in means of −4.43 (−5.76; −3.1, p < 0.001) for understanding, −1.17 (−1.49, −0.84, p < 0.001) for appreciation, −1.29 (−1.79, −0.79, p < 0.001) for reasoning, and −0.05 (−0.9, −0.01, p = 0.022) for expressing a choice. Even if schizophrenia patients have a significantly decreased decision-making capacity compared to non-mentally-ill controls, they should be considered as competent unless very severe changes are identifiable during clinical examination. Enhanced informed consent forms decrease the differences between schizophrenia patients and non-mentally-ill controls (except for the reasoning dimension) and should be used whenever the investigators want to include more ill patients in their clinical trials. Increased age, men gender and an increased percentage of inpatients might increase the differential of decision-making incompetence compared to non-mentally-ill subjects in various dimensions of the decision-making competence as analysed by the MacCAT-CR scale, but the small number of subjects did not allow us (except for one instance) to reach statistical significance.

1 January 2021 in Clinical, Cosmetic and Investigational Dermatology
Verified
Journal Article
Open access
PDF file
Alin Laurentiu TATUAlin Laurentiu TATU
Alin Laurentiu TATU
LBLiliana Baroiu
Liliana Baroiu
SFSilvia Fotea
Silvia Fotea
LALucretia Anghel
Lucretia Anghel
DEDrima Eduard
Drima Eduard
LNLawrence Chukwudi Nwabudike
Lawrence Chukwudi Nwabudike
SARS-CoV-2 has recently been associated with the reactivation of varicella zoster virus in patients. This is potentially an observation of a local susceptibility of the skin in areas of vesicle formation. This article explores the dermatologic manifestations that have been linked to the SARS-CoV-2 virus, their infectious risk, as well as potential confounding factors. An isotopic response may be occurring due to the occurrence of an immunocompromised district incited by sustained inflammation mediated by inflammatory cytokines.

Sorin HostiucSorin Hostiuc
Sorin Hostiuc
Victoria Ioana IonescuVictoria Ioana Ionescu
Victoria Ioana Ionescu
DEDrima Eduard
Drima Eduard
Objective: The main aim of this study was to test whether the use of mouthwash is associated with subtypes of squamous cell carcinoma of the head and neck (SCCHN) and to test the potential risk of SCCHN depending on the mouthwash use duration, frequency, or alcoholic content. Materials and methods: We performed a meta-analysis using Web of Science and Scopus databases to detect the risk change associated with mouthwash use depending on the alcohol content, duration and frequency of use, and anatomical location. We used a random-effects model with the Sidik–Jonkman estimator for effect size model measures. Results: We included 17 studies in the meta-analysis containing 17,085 cases and 20,032 controls. The risk difference for SCCHN between mouthwash users and non-users was minimal, with a value of −0.02 [−0.05, 0.01]. Alcoholic mouthwash use was associated with a minimal decrease in risk (of −0.01 [−0.07, 0.05]). Frequent usage of mouthwash was associated with a statistically significant risk increase for SCCHN but the risk increase was marginal (0.04, [0.01, 0.06]). Conclusions: Overall, our study failed to show a statistically significant correlation between mouthwash use and the risk of SCCHN. The only statistically significant correlation that we could identify was between frequent usage and SCCHN, potentially caused by prolonged contact between some constituents of mouthwash (possibly alcohol) and the oral epithelium.